Hydroxyurea is an anticancer agent used to treat head and neck cancer and sickle cell anemia. It works by inhibiting an enzyme necessary for DNA synthesis, thereby preventing the growth of cancer cells. In sickle cell disease, it increases fetal hemoglobin levels, improving red blood cell shape and function. This drug plays a significant role in managing cancer and sickle cell disease. In summary, Hydroxyurea is effective in treating specific cancers and sickle cell anemia.
Hydroxyurea inhibits ribonucleotide reductase, leading to decreased DNA synthesis and increased fetal hemoglobin production in sickle cell disease.



